Skip to Main Content

Paper Details

The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma.
Scientific Reports
17
2021
ERK, FGF19, FGF19high, FGF19low, FGFR4, FRS2, HCC, HCC cell, Lenvatinib, MKI, hepatocellular carcinoma, lenvatinib, patients, regorafenib, serum FGF19high, sorafenib
Author NameAffiliation
Atsushi IwamaCenter for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo
  • 1 - 1

Datasets

Release 1.2